Wertel Iwona, Okła Karolina, Surówka Justyna, Bilska Monika, Polak Grzegorz, Bednarek Wiesława, Kotarski Jan
I Katedra I Klinika Ginekologii Onkologicznej I Ginekologii Uniwersytetu Medycznego, Lublin, Polska.
Wiad Lek. 2017;70(1):74-80.
Ovarian cancer is a malignancy of high mortality rates. In respect of the number of deaths caused by cancers it occupies the fourth place among women in Poland. Recent studies are focusing on the role of immune system in ovarian cancer pathogenesis. It has been reported that immune response against ovarian cancer cells may be inhibited by a number of immunosuppressive mechanisms active in cancer microenvironment. It causes difficulties in recognizing and destroying cancer cells by immune system which leads to the development of immune tolerance and is associated with a low efficacy of standard therapeutic strategies. In the presented paper we have described selected, new immunosuppressive mechanisms in ovarian cancer patients. They may be a novel, additional and relevant criterion that should be considered whilst developing new therapeutic strategies. Possibly, modulation of immunosuppressive mechanisms could contribute to modifying standard therapies and in consequence improve treatment outcome in ovarian cancer patients.
卵巢癌是一种死亡率很高的恶性肿瘤。就癌症导致的死亡人数而言,它在波兰女性中占第四位。最近的研究集中在免疫系统在卵巢癌发病机制中的作用。据报道,针对卵巢癌细胞的免疫反应可能会受到癌症微环境中多种活跃的免疫抑制机制的抑制。这使得免疫系统难以识别和摧毁癌细胞,从而导致免疫耐受的发展,并与标准治疗策略的低疗效相关。在本文中,我们描述了卵巢癌患者中选定的新免疫抑制机制。它们可能是在制定新治疗策略时应考虑的一个新的、额外的且相关的标准。可能的是,调节免疫抑制机制可能有助于改进标准疗法,从而改善卵巢癌患者的治疗结果。